ArticleNPJ breast cancer2026

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.

Marion T Van Mackelenbergh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.